Kornimate/medical-research-clean huggingface dataset:
3d evaluation of clear aligners versus fixed orthodontic treatment of lower anterior crowding

Conditions: Pathological Resorption of External Root

Summary: evaluate and compare clear aligners versus fixed orthodontic treatment of lower anterior crowding with the use of cone-beam computed tomography within maximum 6 months or until correction of lower anterior crowding whichever is nearest to occur.

group (a): patients will be treated with conventional fixed orthodontic treatment in lower anterior crowding. group (b): patients will be treated with clear aligner therapy in lower anterior crowding.

Eligibility criteria:
inclusion criteria: adult female patients . age 18-25 y . patients with mild to moderate lower anterior crowding (1 mm - 6 mm ) . healthy compliant and motivated patient . full dentition except wisdom teeth . exclusion criteria: previous orthodontic treatments. any systemic disease pregnant and lactating female. pocket depth more than 5 mm.
study on the effects of sacubitril/valsartan on physical activity and sleep in heart failure with reduced ejection fraction patients.

Conditions: Heart Failure, Reduced Ejection Fraction

Summary: the purpose of this study was to investigate the effects of initiation of sacubitril/valsartan vs enalapril treatment on objective measures of both waking activity and sleep in subjects with heart failure with reduced ejection fraction.


Eligibility criteria:
key inclusion criteria: * written informed consent must be obtained before any assessment is performed. * men and women between 18 and 80 years of age * subjects diagnosed with nyha class ii or iii heart failure and with reduced ejection (hfref). (reduced ejection is defined as left ventricular ef ≤ 40%. lvef ≤40% may be determined via any local measurement within the past 6 months prior to signing consent, using echocardiography, multi gated acquisition scan (muga), ct scanning, mri or ventricular angiography provided no subsequent study documenting an ef of \>40%. if the ef measurement is expressed as a value range, the average of the range endpoint values should be used as the ef). * subjects must be a candidate for treatment with sacubitril/valsartan as per uspi. * subjects must be living in a traditional residence, apartment, or non-communal adult home where they can move about freely and frequently and are primarily responsible for scheduling their sleep and daily activities. key exclusion criteria: * subjects with a history of hypersensitivity to any of the study drugs, including history of hypersensitivity to drugs of similar chemical classes, or allergy to aceis, arbs, or nep inhibitors as well as known or suspected contraindications to the study drugs. * subjects with a history of angioedema drug related or otherwise * subjects with symptomatic hypotension or systolic blood pressure \<100 mmhg at screening or \<95 mmhg at randomization * subjects with any conditions in skin or upper extremities which would limit the ability to tolerate a wrist-worn actigraphy device on the non-dominant arm for 24 hours/day for the duration of the study. * subjects who are non-ambulatory or use mobility assistive devices such as motorized devices, wheelchairs, or walkers. the use of canes for stability while ambulating is acceptable. * subjects with physical activity impairment primarily due to conditions other than heart failure such as: * exertional angina inflammatory or degenerative joint disease -gout * peripheral vascular disease * neurologic disease affecting activity or mobility

Keywords: heart failure with reduced left ventricular ejection fraction (lvef) cardiac dysfunction heart muscle dysfunction left ventricular (lv) dilation left ventricular hypertrophy hf ahf chf acute heart failure chronic heart failure congestive heart failure congestive cardiac failure heart failure hreef physical activity actigraphy home sleep test wake
reminder-cue scanning training for homonymous visual field loss

Conditions: Homonymous Hemianopia; Homonymous Quadrantanopia

Summary: this study will evaluate a new approach to training people with visual field loss to scan when driving

homonymous visual field loss is the loss of vision on the same side in both eyes. the most common types are hemianopia (the loss of one half of the field of vision) and quadrantanopia (the loss of one quarter of the field of vision). hemianopia and quadrantanopia may cause difficulties in seeing objects on the side of the field loss. people with these types of field loss can compensate by scanning (looking) toward the side of the field loss. however, sometimes they might not scan sufficiently well resulting in delayed responses to hazards when driving. the purpose of this research study is to evaluate a new approach, "reminder-cue scanning training", to training people with homonymous visual field loss to scan when driving. participants will receive reminder-cue scanning training in the driving simulator.typically there will be three training sessions within about a 2-week period. in addition, participants will complete an evaluation in the driving simulator before and after the training.

Eligibility criteria:
inclusion criteria: * homonymous hemianopia or homonymous quadrantanopia for at least 3 months * binocular visual acuity of at least 20/40 * prior or current driving experience * able to attend multiple study visits * able to communicate in english sufficiently to understand the study procedures exclusion criteria: * physical or general health problems that could impair the ability to operate the controls of the driving simulator or participate in the training
diaphragmatic breathing with and without abdominal muscles strength training program

Conditions: Pelvic Floor Muscle Weakness; Endurance; Quality of Life

Summary: the postpartum period is excessively weak and have hypotonic abdominal muscles, making the ligaments and connective tissue softer and more elastic. the importance of exercise in the postpartum period is very important in this regard. this study will be a randomized control trial used to compare the effects of diaphragmatic breathing with and without abdominal muscles strength training program on pelvic floor strength and endurance and quality of life in postnatal women. subjects meeting the inclusion and exclusion criteria will be divided into two groups using lottery method. assessment will be done using perfect scheme questionnaire and sf- 36 quality of life questionnaire. subjects in one group will receive diaphragmatic breathing exercises along with pelvic muscle strength training and subjects in other group will receive only diaphragmatic breathing exercises. each subject will receive 12 treatment sessions for 4 weeks. results will be analyzed for any change by using spss25.

the postpartum period is excessively weak and have hypotonic abdominal muscles, making the ligaments and connective tissue softer and more elastic. these changes result in anatomical, physiological and biomechanical alterations. therefore, these factors are responsible for the lack of necessary support for the waist region, pain, disability and negative impact on health-related quality of life. the importance of exercise in the postpartum period is very important in this regard. postnatal exercises have several benefits such as improving pelvic floor strength and endurance and quality of life and increasing the general well-being, preventing the diastasis of the rectus abdominis muscle (ram) increasing cardiovascular endurance and bone mineral density. this study will be a randomized control trial used to compare the effects of diaphragmatic breathing with and without abdominal muscles strength training program on pelvic floor strength and endurance and quality of life in postnatal women. subjects meeting the inclusion and exclusion criteria will be divided into two groups using lottery method. assessment will be done using perfect scheme questionnaire and sf- 36 quality of life questionnaire. subjects in one group will receive diaphragmatic breathing exercises along with pelvic muscle strength training and subjects in other group will receive only diaphragmatic breathing exercises. each subject will receive 12 treatment sessions for 4 weeks. results will be analyzed for any change by using spss25.

Eligibility criteria:
inclusion criteria: * age 20 to 35 years. * women between 2 to 6 months post-natal. * women with stable somatic state. * women with no cognitive dysfunction. exclusion criteria: * women with respiratory problems. * women with severe back pain. * patients with any pelvic pathology * patient with any previous neurological disorders

Keywords: abdominal muscles breathing exercises exercise pelvic floor quality of life
a study to evaluate of the efficacy and safety of imsidolimab (anb019) in the treatment of acneiform rash

Conditions: Acneiform Eruptions

Summary: efficacy and safety of imsidolimab in participants with epidermal growth factor receptor inhibitor (egfri)/mitogen-activated protein (map)/extracellular signal-regulated kinase (erk) kinase inhibitor (meki)-associated acneiform rash

this study is a phase 2a, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of imsidolimab compared with placebo in cancer participants with egfri/meki-associated acneiform rash. this study will also characterize the pharmacokinetic (pk) profile of imsidolimab and explore the immune response to imsidolimab in participants with egfri/meki-associated acneiform rash.

Eligibility criteria:
inclusion criteria: * participant has cancer * participant is treated with an oral or injectable food and drug administration (fda)-approved egfri or meki therapy * participant has egfri/meki-related acneiform rash of grade ≥ 2 as per common terminology criteria for adverse events (ctcae) version 5.0, and ≥ 20 inflammatory lesions on the face at screening and day 1. exclusion criteria: * participant has infected egfri/meki-associated acneiform rash according to investigator's evaluation. note: other protocol defined inclusion/exclusion criteria may apply.

Keywords: il-36 receptor interleukin 36 imsidolimab
study to evaluate the safety and clinical activity of ucart123 in patients with bpdcn

Conditions: Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Summary: a phase 1 dose-finding study of universal chimeric antigen receptor t-cells targeting cluster of differentiation (cd) 123 (ucart123) administered intravenously to patients with relapsed or refractory blastic plasmacytoid dendritic cell neoplasm (bpdcn), followed by a dose expansion phase in relapsed or refractory bpdcn patients or newly diagnosed bpdcn patients.


Eligibility criteria:
main inclusion criteria: * patients with a diagnosis bpdcn according to world health organization (who) classification confirmed by hematopathology; * eastern cooperative oncology group (ecog) performance status of 0 or 1;

Keywords: blastic plasmacytoid dendritic cell neoplasm natural killer (nk) cell blastic lymphoma hematologic malignancies cluster of differentiation (cd) cd4+cd56+ hematodermic tumor acute leukemia and myeloid neoplasms chimeric antigen receptor t-cell (car-t) therapy allogeneic cluster of differentiation 4 (cd4) cluster of differentiation 56 (cd56)
efficacy of repeated transcranial magnetic stimulation based on near-infrared imaging in patients with post-stroke depression

Conditions: Stroke; Post-stroke Depression

Summary: this is a randomized controlled trial to evaluate the efficacy and safety of low-frequency repetitive transcranial magnetic stimulation (lf-rtms) in post-stroke depression (psd), explore mechanism of rtms with functional near-infrared spectroscopy (fnirs).

to evaluate the efficacy and safety of low-frequency repetitive transcranial magnetic stimulation (lf-rtms) for the right dorsolateral prefrontal cortex (dlpfc) in patients with post-stroke depression (psd), and explore the possible neural mechanism of rtms with functional near-infrared spectroscopy (fnirs). patients were randomly assigned to the rtms and control groups. the treatment effect was assessed by the hamilton depression scale (hamd), hamilton anxiety scale (hama), national institutes of health stroke scale (nihss), and barthel index (bi). meanwhile, fnirs was used to detect the changes of blood oxygen concentration in the frontal cortex. after treatment, the score of the hamd scale in the rtms group decreased more significantly than in the control group (p\<0.05). the value of ch17 oxyhemoglobin (hbo) and the value of ch6 deoxyhemoglobin (hbr) were decreased after rtms. the hbr of ch6 and ch8 decreased significantly, the hbr of ch12 and ch15 increased significantly (p\<0.05). the hama, nihss and barthel scores improved more significantly in the rtms group.

Eligibility criteria:
inclusion criteria: * 1) hospitalized patients over 18 years of age; (2) meet the stroke diagnostic criteria of the fourth national conference on cerebrovascular diseases and have been confirmed as ischemic or hemorrhagic stroke by head ct and mri; (3) symptoms of psd such as low mood, loss of interest in daily life, insomnia, or poor appetite persist for more than 1 week and meet the inclusion criteria of the dsm-5; (4) hamilton depression scale score-17 (hamd) \> 7; (5) stable vital signs, willing to accept the treatment method of this study, and sign the informed consent for treatment. exclusion criteria: * (1) patients with a history of mental disorders and depression before stroke onset; (2) patients with consciousness disorder, severe aphasia or comprehension and expression disorder after stroke; (3) patients with serious cognitive impairment can not cooperate with the psychological evaluator; (4) patients with metal implants in the skull; (5) people with cardiac pacemakers; (6) previous head trauma, alcoholism, or family history of epilepsy and another risk of seizures; (7) psychotic symptoms such as agitation, speech and behavior disorder; (8) refuse to sign the informed consent.

Keywords: fnirs lf-rtms dlpfc
mechanisms of anabolic osteoporosis therapy

Conditions: Osteoporosis, Postmenopausal

Summary: the aim of this study is to investigate the effect of romosozumab on bone cells during early and late phases of treatment.

the investigators will perform paired iliac crest bone biopsies in postmenopausal women who meet standard romosozumab treatment indications and are being prescribed romosozumab by their treating physician. all study volunteers will have a bone biopsy procedure prior to starting therapy, and then an identical procedure at the contralateral side either 3-6 weeks ("early") or 6-8 months ("late") after starting therapy. this is not a randomized clinical trial testing the efficacy of a drug - the investigators will not be assigning volunteers to a specific osteoporosis therapy, though the investigators will randomize volunteers to either the early or late second biopsy.

Eligibility criteria:
inclusion criteria: all postmenopausal women who are prescribed romosozumab by their treating physicians, meet the fda-defined indication for romosozumab, and who are not at increased risk for a bone marrow aspirate or bone biopsy will be offered enrollment. the fda approved indication for romosozumab is: "the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy." volunteers must be: 1. female aged \> 45 years 2. postmenopausal by either of the following criteria: 1. \> 36 since last spontaneous menses 2. \> 36 months since hysterectomy, plus serum fsh \> 40 units / liter if \< 60 years exclusion criteria: * renal disease (stage 4 ckd) * elevated blood pth (intact pth \> 77 pg/ml). * serum 25-oh vitamin d \< 20 ng/ml * major psychiatric disease that in the opinion of the investigator would preclude the subject from providing adequate informed consent or completing the protocol procedures. * excessive alcohol use or substance abuse that would preclude the subject from providing adequate informed consent or completing the protocol procedures. * known congenital or acquired bone disease other than osteoporosis. * exposure to oral bisphosphonates within the past 3 months, denosumab in the last 12 months, intravenous bisphosphonates within the past 24 months. * exposure to estrogens, serms, or calcitonin, oral or parenteral glucocorticoids for more than 14 days in the past 2 months. * any prior exposure to romosozumab.
a real-world comparison of safety and effectiveness of novel oral anti-coagulant (noac) naïve and warfarin naïve non-valvular atrial fibrillation (nvaf) patients with medicare advantage coverage

Conditions: Atrial Fibrillation

Summary: the primary purpose of this study is to evaluate the risk of major bleeding and stroke/systemic embolism (se) among novel oral anti-coagulant (oac) naïve and warfarin naïve medicare advantage patients with non-valvular atrial fibrillation (nvaf) treated with apixaban, dabigatran, rivaroxaban, or warfarin.


Eligibility criteria:
inclusion criteria: * had at least 1 pharmacy claim for warfarin, apixaban, dabigatran, or rivaroxaban during the identification period (01-jan-2013 through 31-dec-2015) * had continuous health plan enrollment with medical and pharmacy benefits for 6 months pre-index date (baseline period) * had continuous health plan enrollment with medical and pharmacy benefits for at least 1 month following index date * had at least 1 medical claim for atrial fibrillation any time before or on index date exclusion criteria: * had medical claims with a diagnosis code for rheumatic mitral valvular heart disease, mitral valve stenosis or heart valve replacement/transplant during the 6-month baseline period * had medical claims with a diagnosis code for dialysis, kidney transplant, or end-stage chronic kidney disease during the 6 month baseline period * had medical claims indicating a diagnosis of venous thromboembolism during the 6-month baseline period * had claims indicating a diagnosis or procedure code of hip or knee replacement surgery within 6 weeks prior to the index date * had claims for a diagnosis or procedure code for reversible atrial fibrillation * had medical claims indicating pregnancy during the study period * had a pharmacy claim for warfarin, apixaban, dabigatran, edoxaban, or rivaroxaban during the 6-month baseline period * had \> 1 oral anticoagulant prescription claim on the index date
identification of genetic markers for cardiopulmonary diseases (genotype)

Conditions: Cardiovascular Diseases

Summary: this study is designed to investigate whether an association exists between certain genes/protein levels and the development of various cardiopulmonary diseases. it is hoped that this project will provide valuable insight into the understanding of these diseases.

there are two main groups of participants in this trial: group 1: patients that are enrolled in either or both of previous studies: x980515002 study (identification of genetic markers for primary pulmonary hypertension) and or x030403017 study (pulmonary arterial hypertension (pah) database) group 2: participants with the diagnosis of any of the previously listed cardiopulmonary diseases who are ≥15 years of age group 1: for those patients who have had blood samples drawn as a result of participating in the current protocol, identification of genetic markers for primary pulmonary hypertension study (x980515002), we would like to use their previously obtained blood and continue to draw samples (12ml; less than 3 tablespoons) only if they change disease therapies. with each disease therapy change, blood will be drawn at baseline, at 3-4 month, at 6-8 month, at 12 month, and at 24 month visits. these current x980515002 participants will sign a consent form to participate in this new trial. as for the x980515002 expired patients, we would like to use the previously obtained data only in part for this study that was collected as a result of the x980515002 study. for those patients who participated in pulmonary arterial hypertension (pah) database study (x030403017), these participants will also sign a consent form to participant in this new trial. we would like to use the previously obtained data from the x030403017 in part with this study. with each disease therapy change, a 12ml (less than 3 teaspoons) blood sample will be drawn at baseline, at 3-4 month, at 6-8 month, at 12 month, and at 24 month visits. as for the x030403017 expired patients, we would like to use the previously obtained data in part for this study that was collected as a result of the x030403017 study. group 2: after signing a consent form, these participants will have a 12ml (less than 3 teaspoons) blood sample drawn at baseline, at 3-4 month, at 6-8 month, at 12 month, and at 24 month visits. with each disease therapy change, the blood draws (12ml samples) will begin again at baseline and continue through the 3-4, 6-8, 12, and 24 month visits.

Eligibility criteria:
inclusion criteria: * participants with the diagnosis of any of the previously listed cardiopulmonary diseases who are ≥15 years of age will be approached and offered the opportunity to participate in this study.

Keywords: pulmonary hypertension hypertension cardiomyopathy arrhythmias